Stig Moller Christensen, International Planning and CRO Manager at ALK-Abelló, joins Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, to discuss patient recruitment & retention strategies.

He outlines the most crucial factors for pivotal studies and what he expects the sponsor on one hand and the external vendor, the CRO, on the other side have to deliver to expedite the recruitment. He discusses the challenges of developing new immunotherapies for patients with allergies. He also talks about the impact of acceleration of patient recruitment into early stage and late stage studies. 

In the second part of the interview, Christensen discusses the move away from past emphasis on price & time in contracts towards future contracts with more quality parameters integrated. He offers his view on the increase of trials in the BRIC countries and the considerations being addressed. Finally, he suggests KPIs and milestones for future considerations on contract discussions.

[inlinead]